A multi-center, open-labelled, randomized controlled extended phase III non-inferiority clinical trial to evaluate the immunogenicity and tolerability of poliomyelitis vaccine (Vero cells), inactivated, Sabin strains administered with or without routine infant vaccines.
VaccineAug 27, 2026 (epub)
Muhammad Atiqul Islam, Syeda Mahjabeen Zehra, Zaubina Kazi et al.
✦ AI-curated · Sources linked
In 30 seconds
This multi-center, open-label, randomized controlled trial evaluated the immunogenicity and tolerability of inactivated poliomyelitis vaccine (sIPV) administered with or without routine infant vaccines in 1442 healthy infants aged 6-8 weeks from Bangladesh and Pakistan. The study found that the seroconversion rates for PV I, II, and III were comparable between co-administration and staggered groups, supporting non-inferiority.
Key findings
- Post-vaccination seroconversion rates for PV I were 90.3% in group C1 and 87.0% in group S1.
- For PV II, seroconversion rates were 91.7% in group C1 and 91.3% in group S1.
- For PV III, seroconversion rates were 86.4% in group C1 and 92.3% in group S1.
- Adverse reactions were reported at similar rates: 92.8% in co-administration and 95.5% in staggered groups.
Why it matters
The findings suggest that co-administration of sIPV with routine infant vaccines is both safe and effective, which could help optimize vaccination strategies in resource-limited settings facing IPV supply issues.